Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Niagen Bioscience ( (NAGE) ) has issued an update.
At the Annual Meeting of Stockholders on June 24, 2025, Niagen Bioscience‘s shareholders approved an amendment to the 2017 Equity Incentive Plan, increasing the available shares by 4.75 million. Additionally, the Employee Stock Purchase Plan was approved, allowing employees to purchase shares at a discounted rate. These decisions are expected to enhance employee engagement and align stakeholder interests with the company’s growth objectives.
The most recent analyst rating on (NAGE) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Niagen Bioscience stock, see the NAGE Stock Forecast page.
Spark’s Take on NAGE Stock
According to Spark, TipRanks’ AI Analyst, NAGE is a Outperform.
The stock receives a strong score driven by robust financial performance improvements and strong technical momentum. The earnings call provided positive insights with significant growth and strategic initiatives. However, the high P/E ratio indicates overvaluation, and declining revenue trends could pose future risks.
To see Spark’s full report on NAGE stock, click here.
More about Niagen Bioscience
Niagen Bioscience, Inc. operates in the biotechnology industry, focusing on developing health-related products and services. The company is engaged in the production and distribution of supplements and other health products, with a market focus on enhancing human health and wellness.
Average Trading Volume: 884,072
Technical Sentiment Signal: Buy
Current Market Cap: $1.06B
Find detailed analytics on NAGE stock on TipRanks’ Stock Analysis page.